Apixaban: Phase III data

Bristol-Myers and Pfizer reported data from the discontinued, double-blind, international Phase III APPRAISE-2 trial in 7,392 ACS patients showing that twice-daily 5 mg apixaban plus mono or dual antiplatelet therapy

Read the full 306 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE